Download presentation
Presentation is loading. Please wait.
Published byAnnabelle Sherman Modified over 5 years ago
1
Bone 2014;61:191 (Fig. 2) Reproduced from Bone, 61: , Copyright (2014), with permission from Elsevier.
2
Inner Transitional Zone
Compact cortex Outer transitional zone Trabecular Compartment Inner Transitional Zone Bone 2014;59:173 (Fig. 2) Reproduced from Bone, 59:173-9, Copyright (2014), with permission from Elsevier. –2.0 –1.0 0.0 1.0 6 12 a,c a,b,c,d b a –1.5 –1.0 –0.5 0.0 0.5 6 12 a,c a,b,c,d a,b –1.5 –1.0 –0.5 0.0 0.5 6 12 a,b,c,d a,c 0.3 0.2 0.1 0.0 –0.1 6 12 a a,c a,b,c a,b c
3
* * * * * Trabecular Bone Cortical Bone Haversian canal remodeling 8 4
ng/mg dry weight Ibandronate concentration L6 Vert total prox diaph distal Cortical Bone Haversian canal remodeling Active area Labelled surf (mm2) (%) Tibia cortical bone 8 4 0.4 0.2 1.0 0.5 Trabecular Bone MS/BS (%) BFR/BV mm2/mm2/yr AF (/yr) 0.4 0.2 0.0 4 2 * * * Mean (SD) Adapted from Bone, 31:45-55, Copyright (2003), with permission from Elsevier. 2000 1000 Ultimate load (N) Femoral Neck Endoortical surface MS/BS (%) 16 8 * 2000 1000 Ultimate load (N) Vertebrae * 3
4
J Bone Miner Res 2014;doi:10.1002/jbmr.2211 (Fig. 1)
Reproduced from J Bone Miner Res 2014;doi: /jbmr.2211 with permission of the American Society of Bone and Mineral Research.
5
J Bone Miner Res 2014;doi:10.1002/jbmr.2211 (Fig. 3)
Reproduced from J Bone Miner Res 2014;doi: /jbmr.2211 with permission of the American Society of Bone and Mineral Research.
6
J Bone Miner Res 2014;doi:10.1002/jbmr.2194 (Figs. 2, 5)
Reproduced from J Bone Miner Res 2014;doi: /jbmr.2194 with permission of the American Society of Bone and Mineral Research.
7
Osteoporos Int 2014;25:367 (Fig. 2)
Reproduced from Osteoporos Int 2014;25: with permission from Springer.
8
Osteoporos Int 2014;25:367 (Figs. 3, 4)
Reproduced from Osteoporos Int 2014;25: with permission from Springer.
9
Earlier Postmenopause
Premenopause Earlier Postmenopause Later Postmenopause Placebo Risedronate Risedronate % Change Controls Risedronate 5 4 3 2 1 -1 -2 ** * CC OTZ trabecular Porosity vBMD % Change 1 0.5 -0.5 -1.0 Controls Risedronate *,** * CC OTZ trabecular Porosity vBMD Adapted from J Bone Miner Res 2014;29:380-8 with permission of the American Society of Bone and Mineral Research.
10
J Bone Miner Res 2014;29:166 (Figs. 2, 3)
Reproduced from J Bone Miner Res 2014;29: with permission of the American Society of Bone and Mineral Research.
11
Osteoporos Int 2014;25:1163 (Fig. 1)
Reproduced from Osteoporos Int 2014;25: with permission from Springer.
12
Osteoporos Int 2014;25:1163 (Figs. 2, 3)
Reproduced from Osteoporos Int 2014;25: with permission from Springer.
13
J Bone Miner Res 2014;doi:10.1002/jbmr.2188 (Fig. 4)
Reproduced from J Bone Miner Res 2014;doi: /jbmr.2188 with permission of the American Society of Bone and Mineral Research.
14
Bone 2014;61:149 (Fig. 2) Reproduced from Bone, 61:149-57, Copyright (2014), with permission from Elsevier.
15
Bone 2014;61:149 (Fig. 4) Reproduced from Bone, 61:149-57, Copyright (2014), with permission from Elsevier.
16
Bone 2014;59:139 (Fig. 3) Reproduced from Bone, 59:139-47, Copyright (2014), with permission from Elsevier.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.